

CIRM's Discussion with the ICOC Strategic Plan 2012

Ellen G. Feigal, M.D.
Senior Vice President, Research and Development

ICOC
October 26, 2011

Context and objectives for today's session...




- CIRM adopted a strategic plan in 2006, updated in 2009/2010, received recommendations from an External Review Panel in 2010, and these recommendations, shifts in the field, ICOC discussions, and stakeholder input will inform the 2012 update through ICOC consideration in March.
- Engage in a collaborative, consultative and inclusive discussion, encompassing a range of ICOC viewpoints and approaches, early in the process of revising the strategic plan, with a focus on strategic objectives and strategies
 - Today is one of several discussions with ICOC as the strategic plan evolves, gathering inputs from various stakeholders including patients, patient advocacy organizations, researchers, members of industry and other members of the public.




The Vision

Mission

“To support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics, and research technologies to relieve human suffering from chronic disease and injury”





CIRM activities towards our scientific mission




- 453 research and facilities awards
- 59 Institutes/Companies with CIRM awards
- 12 new institutes and centers of regenerative medicine ~\$1 B (\$271M from CIRM)
- \$1.35 B allocated
- Over 900 major scientific papers published (24% high impact journals)
- Over 100 new major stem cell researchers in California
- 14 Disease Teams (preclinical) awarded – up to \$20 M/award aimed for IND (FDA) within 4yrs
- First Clinical RFA awarded for hESC derived therapy, patients enrolling




Trajectory started with establishing shared labs, research leaders and seed funding



CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE



* through 0911



CIRM's Award Allocation




Programs for Creating a Stem Cell Infrastructure





Building Physical Infrastructure
Shared Labs
Major Facilities

Creating an Intellectual Infrastructure
Training I, II
Bridges I, II
Creativity Awards
New Faculty I, II
Research Leaders



Programs cover product development spectrum



CIRM Industry Engagement Initiatives



Strategic Partner Funding Program


- Offers a streamlined procedure to provide funding to programs demonstrating commercial validation
- Pending final Board approval

Regenerative Medicine Pharma & Investor Partnering Conference



- CIRM researchers to be featured
- Premier event for regenerative medicine industry

Patent funding and Technology Transfer Support



\$5M allocated for Technology Transfer Support Program being developed



Perspectives on strategic objectives, strategies, and rationale for change



What would success look like?



Proposed changes to strategic objectives

2009/2010 Strategic Objectives	Acceleration of Therapeutic Discoveries	Operational Excellence	Regulatory Certainty	Public Education	Economic Benefit to California
Rationale for Change	Morph into science and medical benefit	Underpins all objectives	Turn into a strategy	Morph into social benefit	Remains

Draft Strategic Objectives for 2012	<u>Scientific</u> Accelerate understanding of stem cell science and its applications towards human diseases and injuries	<u>Medical</u> Advance science into clinical trials to achieve preliminary evidence of therapeutic benefit to patients	<u>Economic</u> Drive economic development for California from stem cell science	<u>Social</u> Increase awareness of California as the leader in stem cell research and therapies
-------------------------------------	------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------

Proposed strategies

Draft Strategic Objectives 2012	<u>Scientific</u> Accelerate understanding of stem cell science	<u>Medical</u> Advance science into clinical trials	<u>Economic</u> Drive economic development for California	<u>Social</u> Increase awareness of California as leader in stem cell research, therapies
Strategies	<ul style="list-style-type: none"> ▪ Enhance footprint (intellectual, IP, and physical infrastructure) ▪ Build partnerships with industry ▪ Increase scientific research collaborations ▪ Leverage expertise ▪ Revise prioritization and decision making framework 	<ul style="list-style-type: none"> ▪ Prioritize at all stages of the process ▪ Ensure that there is a pathway forward (regulatory, commercial) ▪ Build partnerships with industry, medical community, and global organizations ▪ Engage patients and advocates early 	<ul style="list-style-type: none"> ▪ Leverage investment through partnership ▪ Engage California government and Economic development agency to bring companies to California 	<ul style="list-style-type: none"> ▪ Communicate value proposition ▪ Broaden communication, education, and messaging ▪ Partner with patient advocacy groups and the state of California ▪ Increase global outreach efforts

